

Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression

Radim Moravec, Rao Divi, Mukesh Verma

Radim Moravec, Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, United States

Rao Divi, Mukesh Verma, Methods and Technologies Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, United States

Author contributions: Moravec R wrote the paper; Divi R and Verma M contributed equally by providing guidance and editorial review.

Supported by Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, Rockville, MD 22805, United States.

Conflict-of-interest statement: The authors have no conflicts of interest to report in preparing this work including but not limited to financial, commercial, personal, political, intellectual or religious interests.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Correspondence to: Mukesh Verma, PhD, Branch Chief, Methods and Technologies Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Rockville, MD 20850, United States. vermam@mail.nih.gov
Telephone: +1-240-2766889
Fax: +1-240-2767921

Received: January 4, 2017

Peer-review started: January 7, 2017

First decision: February 17, 2017

Revised: March 4, 2017

Accepted: March 23, 2017

Article in press: March 24, 2017

Published online: June 15, 2017

Abstract

Pancreatic cancer (PC) is a leading cause of cancer-related death worldwide. Clinical symptoms typically present late when treatment options are limited and survival expectancy is very short. Metastatic mutations are heterogeneous and can accumulate up to twenty years before PC diagnosis. Given such genetic diversity, detecting and managing the complex states of disease progression may be limited to imaging modalities and markers present in circulation. Recent developments in digital pathology imaging show potential for early PC detection, making a differential diagnosis, and predicting treatment sensitivity leading to long-term survival in advanced stage patients. Despite large research efforts, the only serum marker currently approved for clinical use is CA 19-9. Utility of CA 19-9 has been shown to improve when it is used in combination with PC-specific markers. Efforts are being made to develop early-screening assays that can detect tumor-derived material, present in circulation, before metastasis takes a significant course. Detection of markers that identify circulating tumor cells and tumor-derived extracellular vesicles (EVs) in biofluid samples offers a promising non-invasive method for this purpose. Circulating tumor cells exhibit varying expression of epithelial and mesenchymal markers depending on the state of tumor differentiation. This offers a possibility for monitoring disease progression using minimally invasive procedures. EVs also offer the benefit of detecting molecular cargo of tumor origin and add the potential to detect circulating vesicle markers from tumors that lack invasive properties. This review integrates recent genetic insights of PC progression with developments in digital

pathology and early detection of tumor-derived circulating material.

Key words: Circulating tumor cells; Digital pathology; Early detection; Exosomes; Pancreatic cancer

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Pancreatic cancer (PC) is a leading cause of cancer-related death. PC mutations accumulate 20 years before patient death with metastatic mutations occurring late in the process. Metastatic risk increases dramatically when tumor diameter is greater than 1 cm. Most PC cases are diagnosed at late metastatic stages when survival is short. Outcomes could be improved if non-invasive methods could detect early stages of the disease and guide treatment decisions. Recent studies indicate this may be possible with application of digital pathology imaging, screening of CA 19-9 with additional markers, and detecting circulating tumor material in early-stage PC patients.

Moravec R, Divi R, Verma M. Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression. *World J Gastrointest Oncol* 2017; 9(6): 235-250 Available from: URL: <http://www.wjgnet.com/1948-5204/full/v9/i6/235.htm> DOI: <http://dx.doi.org/10.4251/wjgo.v9.i6.235>

INTRODUCTION

Pancreatic cancer (PC) is the third leading cause of cancer-related death in men and women in the United States surpassing breast cancer^[1,2]. Projections indicate PC will outpace colorectal cancer and become the second leading cause of cancer-related death in the United States by 2020^[2]. The majority of pancreatic tumors (90%) are classified as adenocarcinomas arising from the ductal epithelium with an annual incidence of 45220 patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) in the United States^[1,3]. Estimates suggest that only 1.3%-10% of patients diagnosed with PC have familial basis for the disease where a genetic component is inherited from a relative^[4]. The remaining majority of PDAC cases display large genomic heterogeneity^[5]. Five-year survival is about 25% for localized stages but only 2% for advanced disease^[1]. The best curative treatment is surgical resection, if performed early it presents a 5-year survival in 25%-30% lymph node negative patients but only 10% for those with positive lymph nodes^[6-8]. Less than 20% of PC cases are diagnosed early enough for surgical intervention^[2]. Relapse rate after surgery is typically high (80%) for this type of cancer and surgery is often followed by adjuvant chemotherapy or chemoradiation^[2,9]. Approximately 80% of PDAC patients are diagnosed late when the disease becomes locally advanced or metastatic, where palliative chemotherapy

is the only treatment option^[10]. Since 1997, Gemcitabine has been commonly used over 5-fluorouracil (5-FU) albeit with only a modest median overall survival (OS) advantage of 5.6 mo (Gemcitabine) vs 4.4 mo (5-FU) in patients presented with advanced stage^[11]. Extensive efforts have been made over the past decade, including numerous randomized phase III clinical trials, to evaluate combinatorial drug treatments for patients with advanced disease^[12]. To date erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, plus gemcitabine is the only course with a targeted therapy agent approved by the United States Food and Drug Administration (FDA) for first-line use in advanced PC^[13-15]. FOLinic acid, Fluorouracil, IRINotecan, and OXaliplatin (FOLFIRINOX) and nab-paclitaxel/gemcitabine have emerged as combinatorial treatments with results that may reach the one-year survival barrier^[16,17]. Adjuvant combination chemotherapy comprising gemcitabine with capecitabine has also shown statistically improved survival over gemcitabine monotherapy in PDAC subjects (ESPAC-4, Phase 3)^[18]. Great focus has been extended into developing methods for improving early detection of the disease and exploring alternate treatment options that can extend survival in patients with late stage presentation^[14]. This review provides description of the genetic fingerprints that drive disease progression and discusses selected features relevant to detection and treatment in this biological context. We further highlight recent advances in digital pathology, improvements in CA 19-9 testing, and detection of circulating tumor cells and tumor-derived extracellular vesicles (EVs) in biofluids of PC subjects (Table 1). Particular attention is made to literature that provides examples of material isolated from human PC subjects along with cell culture or animal model systems that explore mechanistic underpinnings.

PC PROGRESSION AND GENETICS

Computational modeling of primary pancreatic tumors supports the observations that metastatic probability increases exponentially with tumor size^[19,20]. A patient with a primary tumor size of 1 cm in diameter is predicted to have a 28% probability of harboring metastasis at the time of diagnosis. This dramatically increases to 73% probability with a tumor size of 2 cm and elevates to 94% chance for a tumor size of 3 cm^[20]. This clearly suggests that systemic treatments that target rapidly growing cells need to be administered early before log-phase growth is reached. For conventional therapies to improve survival, it will become paramount to detect early lesions before significant invasion takes course. The term pancreatic intraepithelial neoplasia (PanIN) was first coined in 1999 to describe ductal lesions which form as precursors to invasive cancer^[21]. A progression model was soon after proposed where *HER-2/neu* overexpression and *KRAS* mutations are observed early, *p16 (CDKN2A/INK4a)* gene inactivation occurs at intermediate stages, with inactivation of *p53*, *DPC4*, and *BRCA2* occurring late^[21].

Table 1 Summary of demonstrated clinical uses for digital pathology, circulating tumor cells and extracellular vesicles for pancreatic cancer

	Digital pathology	CTCs	EVs
Screening in population	Relies on invasive biopsies	Detection of KRAS mutations ^[92]	Early detection possibility (GPC1+ EVs) ^[117]
Diagnosis	Differential diagnosis of mucinous cancers ^[62]	Pancreatic CTC detected by ISET ^[82] and CellSearch ^[81]	GPC1+ EVs detected in IPMNs ^[117] EVs express mutated KRAS and p53 in PDAC serum ^[123] EVs detected in pancreaticobiliary cancers ^[124]
Staging	Early stage detection in mice ^[60]	(C-MET, CK20, CEA) + CTCs elevated in late stages ^[96]	miR-17-5p in serum exosomes correlates with stage ^[128]
Prognosis	Distinguish Grade I / II in humans ^[61] Potential	CTC positivity has prognostic value in locally advanced pancreatic cancer ^[81] CK20 expression in CTC indicates shorter overall survival ^[94]	Potential
Monitor treatment	Potential	CTC levels decrease during 5-FU therapy ^[91]	Potential
Drug sensitivity/ pharmacokinetics	CT scans can predict drug transport ^[35]	CTC apoptosis can be detected after 5-FU therapy ^[91]	Demonstrated for breast cancer ^[111]
Monitor recurrence	Potential	CTC positivity correlates with postoperative staging ^[94-97]	potential

EVs: Extracellular vesicles; CTCs: Circulating tumor cells; 5-FU: 5-Fluorouracil; PDAC: Pancreatic ductal adenocarcinoma; CT: Computed tomography; PDAC: Pancreatic ductal adenocarcinoma; CEA: Carcino-embryonic antigen.

This model predicts that PC evolves slowly with defined mutational characteristics and presents clinically at late stage. This progression paradigm of gradual pace has recently been challenged by Notta *et al.*^[22] who propose a punctuated equilibrium hypothesis where tumorigenic mutations arise from a cataclysmic event that rapidly leads to invasive cancer and metastasis. Data from this model suggests PC development is neither gradual nor follows the accepted mutation order which may be supported by observations showing that not all clonally expanded precursor lesions lead to a tumor lineage^[5,22,23].

Recent evidence suggests that the development of metastatic cancers from primary tumors can take up to two decades, based on genomic sequence comparisons and mathematical analysis. The development of parental clones from an initiated tumor cell is estimated to take an average of 11.7 years, with an additional 6.8 years for expansion of metastatic subclones, and another 2-3 years before tumors disseminate to distant organs leading to patient death^[24]. The founder mutations present only in the parental clones accumulate in a large number of driver genes involved in tumorigenesis such as *KRAS*, *TP53* and *SMAD4*. The resulting subclones, giving rise to metastatic lesions, contain additional progressor mutations which vary highly among subclones^[24]. This suggests that distant metastasis occurs late during the genetic evolution of PC also supporting the punctuated equilibrium model of progression. These observations are consistent with findings that show more than 50% of the genomic rearrangements occur early during tumor progression being present in both primary and metastatic clones in the patient^[25]. If these rearrangements could be narrowed to distinct genes or protein signaling pathways, they could serve as powerful targets for therapeutics made highly effective by reaching both primary and

metastatic sites. In addition to identifying mutation hotspots in metastatic clones, it will be important to compare founder mutations in primary tumors between patients with different survival outcomes to discover early factors that commit patients to a high risk course^[26].

PCs were shown to have gene expression alterations in 69 gene sets, half of which cover at least twelve core signaling pathways with functional relevance in 67%-100% of observed neoplasias^[27]. Even though these 12 overlapping cascades appear to be genetically altered in majority of the tumors, alterations of the pathway components themselves vary greatly between individual tumors^[27,28]. This implies that therapies directed against these actionable targets may need to implement multi-targeted approaches based on selected patient subgroups, or consist of cocktails that effectively abolish entire signaling cascades^[14,29].

A recent study performing whole-genome sequencing and copy number variation (CNV) analysis found a total of 857971 point mutations, insertions and deletions in 100 samples of PDAC^[30]. The four most commonly mutated genes observed in PDAC patients are the oncogene *KRAS* (75%-90%), tumor suppressor genes *TP53* (74%), *CDKN2A/p16* (35%), and *SMAD4* (31%), along with inactivating mutations in the Rac exchange factor *PREX2*, the tumor suppressor *RNF43*, and the histone demethylase *KDM6A* observed in 10%-18% of subjects^[30]. Focal amplification of druggable oncogenes such as *ERBB2*, *MET*, *FGFR1*, *CDK6*, *PIK3R3* and *PIK3CA* is observed at very low prevalence among only 1%-2% of patients^[30]. Levels of protein expression or activity were not determined in these studies, however, to understand the functional significance of the focal amplifications. Integrated genomic analysis of PDAC identified 32 mutated genes that comprise 10 signaling

pathways: KRAS, transforming growth factor (TGF)-beta, WNT, NOTCH, ROBO/SLIT signaling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing^[31]. Four tumor subtypes were identified based on differential expression of transcription factors and downstream targets: Squamous, pancreatic progenitor, immunogenic, and aberrantly differentiated endocrine exocrine (ADEX) tumors. These tumor subtypes were sorted by gene programs to identify genetic factors that impact OS in PDAC subjects^[31].

PDAC primary tumors can also be sorted into three distinct subtypes based on gene expression patterns and drug sensitivity: Classic, quasimesenchymal and exocrine-like^[32]. The classic subtype, more sensitive to the EGFR inhibitor erlotinib, expresses high levels of adhesion-associated epithelial genes such as *AGR2*, *S100BP* and *GATA6*. The quasi-mesenchymal subtype is more sensitive to gemcitabine and expresses high levels of mesenchymal genes such as *TWIST1* and *S100A2*. The exocrine-like subtype has high expression of tumor cell derived digestive enzyme genes such as *REG3A* and *PRSS1*^[32]. These findings open the possibility for stratifying patients based on tumor gene expression patterns as a means for predicting drug sensitivity.

Taken together, these observations demonstrate that primary and metastatic tumors of the pancreas are highly heterogeneous and contain several distinct clonal populations with unique molecular signatures which develop over a long period of time. This makes targeted therapy difficult, unless common pathways are found that can be effectively blocked by personalized drug regimens^[5].

PANCREATIC STROMA

Another source of genetic diversity can be found within the pancreatic stroma. PDAC cells are surrounded by a rich stroma that is typically far more abundant in cell types other than the tumor. Pancreatic stroma contains a variety of cells including stellate cells, immune cells, fibroblasts, vascular endothelial cells and the extracellular matrix which make up the tumor micro-environment (TME)^[33]. TME plays a pivotal role in tumor behavior including proliferation, drug resistance, invasion and localized immune response^[33,34]. A clinical study investigating intraoperative gemcitabine infusions during PDAC resection showed that high stromal density inhibits hENT1-mediated drug incorporation into the tumor^[35,36]. Investigators in this study derived mass transport parameter (MTP) cutoff values based on expression of the nucleoside transporter hENT1 in the tumor, and pancreatic stromal density scores calculated from CT scans^[35]. Applying MTP cutoffs to a cohort of 110 patients, who received gemcitabine therapy, revealed a 5-year survival rate of 40% in subjects with favorable transport parameters compared to a 15% survival rate in subjects who did not reach the parameter cutoff point^[35]. This study demonstrates that stromal density and drug transport properties can be measured during surgery, using routine contrast-enhanced CT scans

and immunohistochemistry, as a highly effective means for predicting significant response to cancer therapy. hENT1 expression in tumor cells permits bidirectional transport of pyrimidine nucleosides such as gemcitabine, capecitabine and 5-FU^[37]. High expression of hENT1 in PC patients treated with gemcitabine is predictive of improved survival^[36,38,39]. These studies open the possibility for determining drug sensitivity in resected patients through screening morphological features of the stroma combined with assessment of pharmacogenomic profiles^[40].

The pancreatic stroma is enriched with large diversity of constituents, making it difficult to score clinically. A recent study applied a blind source separation technique called non-negative matrix factorization (NMF) to analyze gene expression from a microarray dataset that included 145 primary and 61 metastatic PDAC tumors in comparison to 134 normal tissue samples^[41]. This technique effectively generated gene expression signatures sorted by tumor, stromal and normal cellularity. Patients that were identified with a "classical" tumor subtype had a median survival of 19 mo compared to patients with a "basal-like" tumor subtype that demonstrated a significantly worse survival of 11 mo. Additionally, two stromal subtypes were identified in patients: A "normal" subtype with 24 mo-median survival and an "activated" stromal subtype with significantly worse median survival of 15 mo. These techniques lead the way for identifying genetic markers that may otherwise be obscured by confounding material from normal and stromal tissue^[41].

Mounting evidence supports the hypothesis that pancreatic TME s play a significant role in pathological outcome and treatment response and should therefore be clinically evaluated as a standard practice. The use of digital imaging combined with pharmacogenomic analysis could extend the application of existing treatments for personalized medicine. Best clinical outcomes come from early diagnosis of the disease. Leveraging the biological properties of pancreatic adenocarcinomas and their surrounding micro-environment for early detection and diagnosis would provide maximum benefit for patient survival.

CURRENT DIAGNOSTIC METHODS USING SERUM

Presently, there are no suitable PC screening strategies effective for early detection of PC in the general population. Diagnosis of PDAC is made by pathological assessment of a tissue biopsy. The current gold standard is *via* an endoscopic ultrasound technique coupled with fine needle aspirations (EUS-FNA) which has a sensitivity of 75%-94% and specificity of 78%-95%^[8,42]. For patients who have non-diagnostic FNAs or cannot undergo endoscopy, treatment decisions are based on imaging or determining CA 19-9 serum levels^[8]. The only serum biomarker approved by the FDA for PC is the sialylated Lewis (a) blood group antigen CA 19-9 which is not tumor specific and is frequently elevated during many malignancies,

Table 2 Clinical uses for biomarker panels that increase predictive value of CA 19-9 for pancreatic cancer

	CA 19-9	Sensitivity	Specificity	Ref.
Screening in population	EUS-FNA	75%-94%	78%-95%	[42]
	CA 19-9 ¹	60%-70%	70%-85%	[45,46]
Differential diagnosis	CA 19-9	60%	83%	[44]
	CA 19-9 + CA 125	87%	77%	[44]
	CA 19-9 + ICAM-1 + OPG	78%	94%	[49]
	CA 19-9 + CEA + TIMP-1	71%	89%	[49]
Staging	PAM4-reactive mucins	76%	85%	[51]
	CA 19-9 + PAM4-reactive mucins	84%	82%	[51]
Monitor treatment	Response to chemotherapy			[47]
Monitor recurrence	Low levels post-surgery			
	correlate with survival			[45]

¹Values reflect subjects presented with pancreatobiliary disease. EUS-FNA: Endoscopic ultrasound and fine needle aspiration; OPG: Osteoprotegerin; ICAM-1: Intercellular adhesion molecule 1; CEA: Carcinoembryonic antigen; TIMP-1: Tissue inhibitor of metalloproteinases 1; clivatuzumab monoclonal antibody (PAM4) to MUC5AC.

pancreatitis, cholangitis, obstructive jaundice, hepatobiliary cancer, and benign biliary obstruction^[43,44]. CA 19-9 alone has not been shown to be an effective screening marker for PDAC among the general population based on most studies^[45]. However, sensitivity (60%-70%) and specificity (70%-85%) of CA 19-9 improve significantly in patient cohorts presented with pancreatobiliary disease^[45,46]. Low serum CA 19-9 levels following surgery correlate with improved survival^[45]. Oncologists occasionally use CA 19-9 to track response to chemotherapy but the predictive significance of CA 19-9 for this purpose has reported some variability^[43,45,47].

Measuring CA 19-9 in combination with other markers such as CEA, CA242, and TIMP1, however, was shown to improve its predictive value (Table 2)^[45,48,49]. Barnett *et al.*^[49] could identify PDAC patients using two independent panels: CA 19-9, CEA, and TIMP-1; and a second panel containing CA 19-9, ICAM-1, and OPG. Both panels demonstrated increased sensitivity and specificity over CA 19-9 alone (Table 2)^[49]. Recently, O'Brien *et al.*^[44] discovered CA 19-9 (> 37 U/mL) and CA 125 (> 30 U/mL) serum levels can be elevated up to two years before PDAC diagnosis based on a nested case control study. CA 125 has been reported to distinguish malignant from benign PC tumors with 60.8% sensitivity and 83.3% specificity which improved to 87.8% and 77.8% respectively when combined with CA 19-9^[50]. PAM4, an antibody which binds mucin MUC1 and MUC5AC epitopes expressed in PC, was capable of identifying 64% of stage I PDAC patients with high discriminatory power compared to those with benign pancreatic disease^[51]. PAM4 is capable of distinguishing normal pancreas from PanIN-1A, PanIN-1B, PanIN-2, and PanIN-3 lesions, intraductal papillary mucinous neoplasia (IPMN) lesions, as well pancreatic adenocarcinomas of various grades^[52]. Combining CA 19-9 with a PAM4-reactive marker improved sensitivity (84%) without a loss in specificity (82%) in a serum-based enzyme immunoassay (EIS)^[51]. Despite some propensities for false positivity, CA 19-9 continues to be a benchmark serum marker for evaluating PC in the clinical setting. It will be important

to test combinations of other markers in addition to CA 19-9 to improve its diagnostic utility in larger populations.

TUMOR IMAGING AND DIGITAL PATHOLOGY

In addition to biopsies and serum marker tests, lesions and primary tumors can be characterized by clinical imaging. Computed tomography (CT) and magnetic resonance imaging (MRI) are the most frequently used imaging method for diagnosis and clinical staging^[33,43]. Additional screening approaches using imaging modalities include endoscopic ultrasonography (EUS), magnetic resonance cholangiopancreatography (MRCP), and endoscopic retrograde cholangiopancreatography (ERCP)^[4]. However, these approaches are limited to surveillance centers with robust PC programs and are typically only performed on high-risk patients^[53,54]. MRI and EUS have been proposed for use as first line modalities but often fail to distinguish benign from malignant lesions^[55]. Emerging imaging modalities and molecularly targeted imaging agents are of great interest as early detection strategies but may be cost prohibitive and inaccessible to many patients^[56].

Upon diagnosis, patients are staged based on the AJCC 7th Edition Staging Manual criteria before proceeding to surgery^[8,57]. This is typically accomplished through cross-sectional imaging (CT or MRI) along with tissue biopsy^[8]. Among those staged with resectable disease by biopsy, only 70%-85% actually present with resectable tumors, intraoperatively^[8]. This indicates a need for improvements in staging methodology which may be enhanced by digital pathology^[8]. The field of digital pathology has recently grown to complement histological diagnosis performed by pathologists^[58]. These methods extract and quantify histological features from whole slide images thus improving on the subjective nature of the work^[59].

Langer *et al.*^[60] developed a method that can accurately predict early pancreatic lesions with a 93% success rate

in an independent test set using tissue obtained from mouse models of early-stage PDAC. The program uses a top-down object learning paradigm similar to the methodology used by human pathologists. Initially, ducts, nuclei and tumor stroma are identified and segmented. From those, secondary morphological features such as duct deformation and nuclei malformations are measured. These data sets are then used to train a predictive model that distinguishes normal tissue from premalignant cancer lesions^[60]. Similar techniques can be extended to accomplish classification of PDAC by grade using human tissue samples^[61]. Diagnosis of PDAC was made based on three parts: Segmentation and feature extraction; model learning and validation; and diagnosis. Training data measuring ducts, consisting of the lumen and epithelial nuclei, can distinguish normal human subjects and those with grade I and grade II PDAC with an accuracy of 94%^[61]. Automated systems have been developed for making a differential diagnosis of rare lesions such as cystic neoplasms of the pancreas using human biopsy tissue^[62]. Song *et al*^[62] were able to distinguish benign serous from malignant mucinous cystadenomas using a computer-aided design technique. Cystic regions were identified and epithelial cells surrounding the lumen were discerned. Three classes of features were analyzed by the program to achieve a differential diagnosis: The number and size of cysts, characteristics of the surrounding epithelium, and indication of mucus production^[62].

Current applications of digital pathology for PC do not offer much more beyond histological diagnosis performed by a pathologist but indicate potential for detecting early lesions. Improvements could be made, for example, by developing digital pathology methods for images annotated with clinical data from population-based repositories. This could potentially aid the discovery of morphological features associated with treatment and survival outcomes.

The intended goal beyond research is to incorporate digital tools into clinical practice as a way to standardize histological diagnosis in patients at high risk of developing the disease. This could improve staging and determination of resectability. Some concerns raised include public health consequences if misdiagnosis is caused by improper use or analysis of poor quality images^[63]. The Food and Drug Administration recently released a guidance for technical performance assessment of digital pathology whole slide imaging (WSI) devices^[64]. Currently, WSI devices are classified as Class II for methods that provide adjunct analysis after a primary diagnosis is made using glass slides. WSI devices which make a primary diagnosis alone are classified as high-risk Class III devices if their intended use is new and lacks a Class II predicate. A *de novo* process provides a less resource-intensive approval path to Class I / II classification if special controls are presented that provide reasonable assurance of safety and effectiveness. A more clearly-defined approval process for manufactures would enhance innovation and commercialization potential of digital pathology instruments and software^[65].

DETECTING TUMOR CELLS IN CIRCULATION

Performing invasive biopsies for routine screening of the general population is not reasonably a feasible option. Detecting tumor material in the blood or other biofluids would be ideal for many reasons. A test assessing a panel of markers in biofluids could be ordered by physicians in most clinical centers, and collected by non-invasive or minimally invasive procedures. Performing additional tests using the same starting material could easily lead to diagnostic refinement. Diagnostic tests can be expanded to cover non-tumor biomaterial such as components of the immune system, blood/serum, pancreatic juice, stool, oral and gut microbiota, and markers of metabolic activity. Given patient variability, measuring systemic profiles of markers not directly derived from tumors may not yield the specificity and sensitivity necessary to accurately determine risk for developing advanced PC. A search for "pancreatic cancer" in the published literature can easily generate over 50000 returns which documented more than 2500 individual genes as potential PC biomarkers due to their overexpression patterns^[66]. A compendium of PC biomarkers identified at least 1000 molecules with evidence of upregulation in precursor lesions^[66]. Early detection of these precursor lesions particularly before invasive cells establish colonization would be ideal.

A critical study, using genetically engineered mouse models of PanIN, showed that cells from preneoplastic lesions can breach the basement membrane and spread into the stroma^[67]. Contrary to conventional wisdom, these cells undergo epithelial-to-mesenchymal transition (EMT) and enter the blood into circulation with no evidence of carcinoma. These findings suggest that EMT transition can occur as an early phenomenon even before histologic emergence of cancer. These cells acquire a mesenchymal phenotype, exhibit stem cell properties, have tumor-initiating capacity, and are most abundantly observed at inflammatory foci^[67]. Induction of pancreatitis and immunosuppressive treatment with dexamethasone have strong effects on dissemination supporting a link between early precursor cell invasion and localized inflammation^[67]. Typical circulating tumor cell (CTC) markers such as EpCAM are expressed in less than 20% of the PanINs in this model system^[67]. This has implications for commercially available methods which may overlook these circulating precursors, because they rely on such epithelial markers for CTC detection.

EMT in primary cells was shown to be associated with acquisition of stem cell-like characteristics^[68]. Both normal and cancer stem cells possess the ability to self-renew and produce differentiated progeny^[29]. Cancer stem cells are further functionally defined by having enhanced tumor initiating capacity when transplanted to a permissive host^[67]. *In vivo*, CTCs detach from the primary tumor and enter the blood where they can be

transported to distant sites with only 0.01% surviving to form metastases^[69]. CTC detection has been extensively used for prognosis (progression free survival and OS) and predicting response to treatment in breast, prostate, colorectal and lung cancers^[70-74]. CTCs have also been detected in PC patient samples but their prognostic potential remains to be optimized outside the limitations of a small sample of subjects^[69,75-77].

CTC DETECTION METHODS

Circulating tumor cells are present at very low concentrations in the blood, typically one CTC per billion blood cells. For this reason, CTCs need to be enriched to differentiate them from the vast hematopoietic cell background, and characterized to verify their tumor origin^[69]. Several enrichment media for density-gradient centrifugation are commercially available including LymphoPrep™ (Axis-Shield), Ficoll-HyPaque™ (Sigma-Aldrich), Oncoquick® (Greiner Bio-One), and RosetteSep™ Human Circulating Epithelial Tumor Cell Cocktail with SepMate™ (StemCell Technologies). Enrichment is typically followed by targeted isolation. Four strategies are available to isolate and capture CTCs: Positive selection using antibodies attached to solid-support, negative selection, cell size-based methods such as filtration, and physical property-based methods^[77]. Most CTC detection methods rely on either positive immunoselection of cells expressing the epithelial cell adhesion molecule (EpCAM) or negative selection by depleting leukocytes from the blood using CD45-binding antibodies^[78]. Commercial immunomagnetic bead separation systems are available including EasySep cell separation (StemCell Technologies), Dynabeads (Invitrogen), CellSearch CTC system (Janssen Diagnostics) and MACS (Miltenyi). CellSearch CTC is the only system approved by the FDA for capturing and enumerating CTCs of epithelial origin by CD45⁺, EpCAM⁺ and cytokeratin⁺ selection^[79]. CellSearch has been cleared by the FDA for management of breast, colorectal and prostate cancers and has also been tested in PDAC patients with detection rates varying from 11%-45%^[44,78,80-85].

Once isolated, circulating tumor cells are typically characterized by immunocytochemical (ICC) staining or nested real-time polymerase chain reaction (RT-PCR). Detection strategies typically assess epithelial mRNA profiles which include *EpCAM*, epithelial carcinoembryonic antigen (*CEA*), *CEACAM5*, *CK19*, *BIRC5* and *MUC1*^[76]. There are currently more than 40 assay platforms for CTC detection and enrichment that have been widely publicized^[86]. Among these, the utilization of microfluidics and microarray technology in CTC detection is expanding.

CTC detection was investigated as a prognostic tool in a LAP07 international multicenter randomized study to assess if patients with locally advanced pancreatic carcinoma (LAPC) would benefit from chemoradiotherapy over continuation of chemotherapy^[81]. Bidard *et al*^[81] were able to achieve a CTC detection rate of 11% using a low cut-off of one or more CTCs/7.5 mL of blood using the

CellSearch system. This is lower than the 50% detection rate typically reported for metastatic PC patients^[84]. CTC positivity nonetheless was a prognostic factor for OS which was lower in CTC positive LAPC patients^[81]. More CTCs can be detected in the blood of PC patients using ISET (Isolation by Size of Tumor Cell) based on a comparative study which found detection of 26 CTCs/7.5 mL blood using ISET compared to 2 CTCs/7.5 mL blood by CellSearch^[82]. ISET also detected CTCs in a much higher proportion of patients (93%) vs CellSearch (40%)^[82]. ISET is a filtration-based, marker-independent method that sorts by cell size and morphology using filter modules offered by a company started by the inventor of the technology (Rarecells Diagnostics)^[87,88]. Thus ISET may offer a significant advantage over CellSearch which relies on expression of EpCAM for CTC identification. PDAC cells, among carcinomas, are more prone to epithelial-mesenchymal transition (EMT) which reduces the expression of EpCAM^[78,89,90]. This presents a problem for PC detection using CTCs as most of the current CTC detection methods rely on EpCAM or other epithelial molecules for CTC detection^[69,86].

CTC CHARACTERIZATION

There exists a critical need for the development of assays that can additionally identify CTCs which undergo EMT and lose expression of typical epithelial surface antigens. Ren *et al*^[91] detected CTCs in peripheral blood of advanced stage PC patients before (in 80% of patients) and after treatment (in 29% of patients) with 5-FU by immunostaining for CA19-9 and CK8/18 expression. The mean concentration of blood CTC decreased from 16.8 cells/7.5 mL of blood before chemotherapy to 3.8 cells/7.5 mL blood after a seven-day cycle of 5-FU chemotherapy^[91]. Evidence of apoptosis induced by 5-FU was observed in CTCs obtained from patients and in pancreatic cell line models (PL45 and PANC-1 cells)^[91]. These studies open the possibility for using CTC assays to monitor chemotherapy efficacy and extent of remission although they fail to selectively identify mesenchymal antigens expressed by CTCs. Other potential mesenchymal protein marker candidates include Cadherin 2, Vimentin, Snail/Slug, zinc finger E-box binding homeobox1 (ZEB1), and Twist family basic helix-loop-helix transcription factor 1 (TWIST1)^[79]. These mesenchymal markers could be combined with PC-specific markers to increase specificity.

To verify tumor origin, isolated CTCs can also be screened for genes expressed or mutated predominantly in PC such as *KRAS*. Court *et al*^[92] detected *KRAS* mutations in 92% of PC patients using a NanoVelcro/laser capture microdissection (LCM) platform. This technique captures CTCs on a microfluidic chip using biotinylated anti-EpCAM antibodies and is followed by identification through ICC staining of CD45, CEA, and staining of pancytokeratin for nuclear morphology. Mutations in *KRAS* were not observed in white blood cells and overall reliability of the assay required isolation of only 10-100 circulating tumor cells^[92]. Chausovsky *et al*^[93] detected the

expression of Cytokeratin 20 (CK20) in 22/28 PC patients using RT-PCR analysis of peripheral blood CTCs. Soeth *et al*^[94] found that CK20 was expressed in CTCs of 33% of patients in a larger cohort ($n = 154$) who had significantly shorter OS. Cytokeratin 7 (CK7) and cytokeratin 20 (CK20) are expressed in a variety of epithelial neoplasms including majority of pancreatic carcinomas (62%)^[95]. A variety of commercial platforms are now available for detection of amplified CTC DNA such as TruSeq Amplicon (Illumina) and Ion Torrent AmpliSeq™ (Life Technologies).

Levels of RNA expression can also be measured by RT-PCR or directly imaged by *in situ* RNA hybridization using platforms such as ViewRNA™ CTC Platform (Affymetrix). Zhou *et al*^[96] measured mRNA expression of *h-TERT*, *C-MET*, *CK20*, and *CEA* by RT-PCR in CTCs isolated by immuno-magnetic enrichment using EpCAM. This method can distinguish PC patients from benign control subjects with high degree of specificity. Further, when pancreatic patients were in later stages, the expression rate for C-MET (67%), CK20 (75%) and CEA (75%) were statistically higher than during earlier stages^[96]. These findings open the utility of CTC detection for monitoring disease progression. Two independent studies have also found that preoperative CTC positivity correlated with postoperative staging^[94,97]. This indicates that in addition to diagnostic value, CTC detection has prospects for PC staging^[8].

The genetic content of CTCs can also be sequenced for molecular discovery^[92]. Yu *et al*^[98] adapted a microfluidic device to capture CTCs which were subjected to single-molecule RNA sequencing. Using a mouse PC model, *Wnt2a* gene was identified to be enriched in CTCs isolated from mice and in 5/11 human PC cases^[98]. Ting *et al*^[99] used focusing-enhanced microfluidic capture of CTCs (CTC-iChip) from primary PC tumors followed by deep-RNA sequencing. RNA-seq profiles identified enrichment of stem-cell-associated genes such as *Aldh1a2* and the extracellular growth factor binding protein *Igfbp5* which localized focally at the tumor epithelial-stromal interface^[99]. CTCs of mouse and human origin also expressed elevated levels of gene expression of the stromal-derived extracellular matrix protein (SPARC), which increases invasive and migratory potential of PDAC cell lines^[99]. Whole exome sequencing of CTCs has been successfully accomplished in metastatic prostate cancer cells, PDACs, and pancreatic carcinoma neoplasms with acinar differentiation^[100-102].

To improve prognostic value, CTC analysis can be combined with other methods such as direct detection of circulating free DNA (cfDNA) in the blood. Mutated *KRAS* cfDNA, isolated from plasma, was observed in 26% of patients with resectable and advanced stage disease and correlated strongly with decreased OS compared to mutant *KRAS* free subjects (60 d vs 772 d)^[85]. Patients with panreatobiliary carcinomas were accurately diagnosed using cfDNA sequencing with a 92% sensitivity and 100% specificity^[103]. CTCs were detected in peripheral blood of 20% of metastatic disease patients using the CellSearch system by CD45 positive cell depletion. CTC

positive PDAC patients had decreased OS of 88 d (95%CI: 27-206) compared to 393 d (95%CI: 284-501) in CTC negative subjects^[85]. Circulating tumor DNA (ctDNA) can also serve as a detection strategy on its own or in combination and can be found in other articles that focus on this topic^[78,104,105]. For example, Berger *et al*^[104] were able to distinguish patients with Intraductal Papillary Mucinous Neoplasm (IPMN) lesions from controls by detecting mutation hot-spots in circulating cell-free DNA from patient blood samples.

Collectively, the utility of circulating tumor cells as a diagnostic marker in PC is gaining more ground. CTC detection offers the benefit of a low-risk safety profile which may be a cheaper alternative to FNA biopsies^[8]. The cost of obtaining a diagnosis by EUS-FNA in the United States can be approximately \$16000 compared to \$370 Medicare reimbursement for the CellSearch CTC-based Assay^[106,107]. A broader range of epithelial and mesenchymal markers are needed to create techniques that adequately capture a wide range of PC-specific circulating tumor cells. Finally, selected CTC techniques need to be tested in larger patient cohorts to pass the same FDA clinical guidelines that made the CellSearch CTC-based assay a successful clinical tool for breast, prostate and colon cancer.

EVS

The study of EVs has gained significant momentum in recent years, because their cargo represents material of tumor which can shed light on the state of disease progression. EVs are membrane-bound organelles secreted by a variety of cells including cancer cells. The cytosol-derived lumen of EVs is enclosed by a lipid-bilayer forming a delivery vehicle for a variety of nucleic acids, proteins and lipids which can be horizontally transferred into recipient cells altering their biological properties. This allows cancer cells to continually modify their local microenvironment as well as distant sites when EVs enter circulation^[108]. Because the molecular composition and function of these organelles represents their tumor origin, insight into EV biology provides great potential for tumor screening, diagnosis and prognosis. However, not all EVs are alike. The subcellular origin determines the type of cargo and mechanism of release from the cell. Large microvesicles (100-1000 nm) that bud outward from the plasma membrane are called ectosomes or ARRDC1-mediated microvesicles (ARMMs)^[109]. Small EVs (30-150 nm) are called exosomes, which originate as intraluminal vesicles found in endosomal membranes and are secreted through fusion of multivesicular bodies (MVB) with the plasma membrane^[110]. Several studies have identified exosomal subtypes based on molecular content that may hold diagnostic and prognostic value for diseases such as PDAC^[110,111].

Exosomes play an active role in disease progression by promoting tumorigenesis, metastasis, tissue remodeling, immune evasion, and chemoresistance^[111,112]. This is reported to be achieved by the delivery of microRNA,

mutated genomic DNA fragments, proteins and lipids which alter the biology of tissues that take up cancer-derived exosomes^[112]. Exosomes offer several detection advantages over other biomarkers. Because exosomes travel across the endothelium into circulation they can be detected in serum and/or urine which can be collected over time when monitoring a patient^[112]. Exosomal content can be dispersed within the lipid membrane bi-layer but can also be found in the lumen where it is protected from degradation by external nucleases and proteases^[113]. Once exosomes are isolated, their content can be much easier to detect by sensitive techniques such as RT-PCR, next generation sequencing, gene expression microarrays, and mass spectrometry^[111,114]. The first challenge in establishing exosome biomarkers as clinical tools depends on the ability to isolate them in sufficient quantity at high purity.

Initial isolation depends on crude physicochemical properties such as particle size, density and solubility. Isolation by differential centrifugation is the most classical method used by the biomedical research community. However, differential centrifugation typically results in low yield and always presents with some degree of contamination^[108]. Recent developments have improved yield and purity through precipitation, affinity-based sorting by magnetic beads, and particle size-based isolation such as ultrafiltration and size exclusion chromatography^[108,113]. Exosome isolation kits are now readily commercially available^[108,115]. The identity and enrichment of exosomes in a biochemical fraction can be further defined by detection of endosome-specific tetraspanins (CD9, CD63, CD81), membrane transport and fusion proteins (flotillin, GTPases), MVB biogenesis-related proteins (Syntenin, Alix, ESCRT, TSG101), and heat-shock proteins (Hsp60, Hsp70, Hsp90)^[110,113,116].

EXOSOMAL CARGO

Given that most cells secrete exosomes, it can be a difficult task to distinguish cancer-specific material to that of healthy cells. When evaluating pathological relevance of exosome studies, purification methodology, exosome identification and presence of cancer-specific markers are essential components that should be taken into consideration. One of the most widely acclaimed PDAC exosome studies was recently presented by Melo *et al.*^[117]. The authors identified the presence of heparin proteoglycan GPC1, in exosomes isolated from breast and PC patients by ultracentrifugation and sucrose density gradient separation (followed by CD9, CD81 and flotillin 1 detection). Baseline GPC1 positivity was found in only 2.3% of healthy donors while elevated GPC1 expression was found in 75% of breast cancer subjects and among 100% of pancreas cancer patients ($n = 190$). Relative concentrations of exosomes were much higher in the sera of cancer patients compared to healthy subjects. GPC1⁺ exosomes were also detected prior to formation of PanIN lesions in 16-d-old mouse models of PDAC (Ptf1a^{cre/+}; LSL-Kras^{G12D/+}; Tgfbr2^{L/L})

with increased proportionality over time. Serum GPC1⁺ exosomes in these models were present in circulation early before the onset of histological signs or MRI-detectable lesions. Further, the authors were able to use GPC1 positivity to distinguish healthy donors and those with benign pancreatic disease (BPD) from patients with histologically validated PC precursor lesions (intraductal papillary mucinous neoplasm-IPMN) with a high degree of specificity (75%) and sensitivity (82%). Taken together, these findings suggest that PC cells secrete elevated levels of GPC1 positive exosomes which may be useful for early detection of tumors even prior to histologic manifestation^[117].

EGFR is a receptor tyrosine kinase (RTK) activated in a subset of PC cells^[118]. Adamczyk *et al.*^[119] found pancreatic cell lines (BxPC3, MiaPaca2, Panc1, Paca44 and A818-4 cells) secrete a 110 kDa soluble form of the EGFR ligand-binding extracellular domain (sEGFR) directly into conditioned media. A 170 kDa intact receptor and a 65 kDa processed form, including the intracellular kinase domain, are secreted as constituents of exosomes. Exosomes were separated from the secretome by ultracentrifugation and confirmed by exosome markers Alix, CD9, CD63 and Syntenin. The full-length EGFR was enriched 20-fold in exosomes along with 1600 other proteins found in the fraction by mass spectrometry^[119]. The reason for compartmentalized release of these processed EGFR forms is currently not known. Soluble EGFR may provide a method for distant receptor transactivation or may confer EGFR positivity in cancer cells lacking EGFR expression. EGFR⁺ exosomes may also enhance drug resistance by serving as a decoy for therapeutic antibodies. This has been observed in HER2⁺ exosomes secreted by breast cancer cells that were shown to inhibit cell proliferation effects of Trastuzumab but not Lapatinib^[120]. The next important step will be detecting EGFR⁺ exosome in healthy and PC patients. Whether these isoforms possess any oncogenic mutations also needs to be explored before clinical use of these exosomes as cancer-specific biomarkers is considered.

KRAS is an oncogene that is mutated in 90% of PC cases^[121,122]. Kahlert *et al.*^[123] isolated large (> 10 kb) double stranded genomic DNA fragments from EVs originating from PC cell lines and from serum of PDAC patients. Exosomes were purified from cell lines (Panc-1, T3M-4) and serum isolated from patients prior to surgical resection using ultracentrifugation after filtration. Exosomes were further verified by expression of CD9, TSG101, and CD63 by FACS analysis. By using whole genome sequencing, the authors demonstrated that PDAC serum exosomes contain not just mutated *KRAS* and *p53* oncogenes but also genomic DNA fragments spanning all chromosomes^[123]. This suggests that genomic fragments can be isolated from purified PC exosomes and sequenced for analysis. Exosomes isolated from peripheral blood and pleural effusions can be sequenced to profile the genomes and transcriptomes of patients with pancreaticobiliary cancers^[124]. Traditional tissue biopsies for these deeply located visceral cancers are difficult to safely acquire in

Table 3 Challenges and potential solutions for pancreatic cancer diagnosis and treatment

Challenges	Potential solutions
Metastatic probability increases dramatically with larger tumor size	Promote development of early detection methods (circulating tumor cells, extracellular vesicles, molecular cargo in CTCs and EVs, cfDNA, ctDNA)
Tumor mutations develop up to two decades with metastatic mutations occurring late in the process	Identify founder mutations that correlate with unusual survival outcomes
Pancreatic stroma influences treatment sensitivity	Promote research on stromal characterization
Transporter expression in the tumor impacts drug delivery	Identify expression features that correlate with treatment sensitivity to a variety of drugs
CA 19-9 is not pancreatic cancer specific	Promote development of assays for biomarker panels that increase CA 19-9 utility that will be eligible for FDA approval
Prediction of resectability is only 70%-85% accurate	Improve staging based on biopsies by implementing clinical use of digital pathology methods
No FDA-approved digital pathology methods exist for pancreatic cancer	Combine digital pathology with accepted primary diagnostic methods and test special controls for digital imaging that will permit FDA application through a more streamlined <i>de novo</i> pathway

CTC: Circulating tumor cells; EVs: Extracellular vesicles; cfDNA: Circulating free DNA; ctDNA: Circulating tumor DNA; FDA: Food and Drug Administration.

less specialized clinical centers. These studies create the possibility of performing genomic panel tests to identify oncogenic material from exosomes isolated from patients suspected of having elevated risk of PC or those where traditional biopsies are not feasible to obtain.

In addition to carrying genomic DNA, exosomes can also directly inhibit translation or target mRNA for degradation through the delivery of microRNA^[125]. Exosomal miR-21, miR-212-3p and miR-203 and have been shown to enhance chronic pancreatitis, modulate immune response, and induce drug resistance^[125-127]. Que *et al.*^[128] found elevated levels of miR-17-5p in serum exosomes of PC patients which correlate with metastatic stage, compared to healthy controls. Levels of exosomal miR-21 were also higher in PC patients vs healthy and chronic pancreatitis subjects but did not correlate with PC differentiation or stage^[128]. The concentration of EVs in serum or plasma is almost one thousand times higher than in urine, a less invasive biofluid where exosomes remain stable at room temperatures for up to a week^[115]. Ymir Genomics has developed a novel precipitation reagent, Ymirite, which isolates extracellular nucleic acids and vesicles from urine samples. Exiqon offers two exosome enrichment kits (miRCURY) for serum/plasma and urine isolation and a qPCR detection system (LNA™) for miRNA detection which enables profiling of biofluids where microRNA levels are extremely low. Further improvements in exosome and oncosome cargo characterization will significantly improve the clinical prospects of EVs.

EXOSOMAL MARKERS THAT INDICATE PATHOGENIC EFFECTS OF PDAC

Once released into circulation, the destination of tumor-secreted exosomes can be directed through expression of membrane proteins that guide cellular targeting such as integrins, tetraspanins, phosphatidylserine receptors and heparin sulfate proteoglycans^[117,129-131]. These features

enable exosomes to reach distant sites where they can exert pathogenic effects secondary to the primary cancer. For example, PDAC derived exosomes have been shown to promote liver metastasis through expression of macrophage migration inhibitory factor (MIF) which induces a fibrotic microenvironment when taken up by liver resident Kupffer cells^[112,132]. PDAC derived exosomes can also secrete TGF-beta which activates hepatic stellate cells to secrete fibronectin which in turn arrests bone-marrow derived macrophages and neutrophils to produce pro-tumorigenic cytokines in the liver^[127,132].

Diabetes is a risk factor for PC but the association is complex^[133]. Studies by Javeed *et al.*^[134] suggest that adrenomedullin (AM), secreted into circulation by pancreatic exosomes, reaches remote pancreatic beta cells to induce beta-cell dysfunction by inhibiting insulin secretion. The authors showed AM⁺ exosomes, isolated by differential centrifugation, are secreted into cultured media by PC patient-derived primary cell lines as well as into portal/peripheral venous blood of PC patients. Additionally, these AM⁺ exosomes also contain CA 19-9 making them an attractive PC biomarker^[134]. Another PDAC-exosomal protein Bip, also impairs insulin secretion through interactions with pro-insulin^[127]. These studies hold promise for potential diagnostic methods which may predict secondary complications to PC.

Detection of exosomes and their cargo presents some attractive qualities as a liquid biopsy technique. Advantages include the ability to capture tumor-derived material circulating before and during metastatic colonization, enable monitoring of treatment effectiveness and recurrence, enhance prognostic capability based on classifying molecular signatures, and serving to indicate secondary complications. Vesicle enrichment methods have been streamlined and standardized through the availability of commercial kits. The discovery of highly cancer-specific exosomal markers such as GPC1 will provide a foundation that could serve as the basis for

accurate and non-invasive diagnostic tests.

CONCLUSION

The genetic evolution of PC is complex and may take up to two decades with metastatic mutations occurring relatively late in the process. Diagnosis is made at late stage where large genetic heterogeneity is observed within the tumor. With genotyping costs decreasing, it may be possible to predict drug sensitivity following resection through a combination of genomic profiling of the tumor, stromal density image processing and transporter expression determination. Digital analysis of the stroma from CT images has demonstrated the ability to predict a significant survival benefit for patients who undergo gemcitabine treatment. These methods pave the way for future applications in digital pathology as a means to increase prognostic potential and augment treatment decisions for personalized medicine.

While there is some room for refining existing treatment options to extend survival of late-stage PC patients, overcoming challenges for early detection of the disease will be paramount to significantly decrease the burden on the population (Table 3). Detecting physiologically relevant markers in exosomes and circulating tumor cells offers an advantage of testing with little or no discomfort to the patient. This creates the possibility to obtain serial samples of body fluids over time to allow monitoring of disease progression while eliminating risks associated with invasive biopsies. Combining information gained from these two types of tests could potentially increase diagnostic potential during early stages of PC development.

ACKNOWLEDGMENTS

This article is dedicated to Sgt. Mark Diehl.

REFERENCES

- 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin* 2015; **65**: 5-29 [PMID: 25559415 DOI: 10.3322/caac.21254]
- 2 Pancreatic Cancer Action Network. Pancreatic cancer facts 2016 [Internet]. 2016. Available from: URL: <https://www.pancan.org/wp-content/uploads/2016/02/2016-GAA-PC-Facts.pdf>
- 3 Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. *Cancer Epidemiol Biomarkers Prev* 2005; **14**: 1766-1773 [PMID: 16030115 DOI: 10.1158/1055-9965.EPI-05-0120]
- 4 Bartsch DK, Gress TM, Langer P. Familial pancreatic cancer--current knowledge. *Nat Rev Gastroenterol Hepatol* 2012; **9**: 445-453 [PMID: 22664588 DOI: 10.1038/nrgastro.2012.111]
- 5 Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. *Nat Rev Gastroenterol Hepatol* 2012; **9**: 435-444 [PMID: 22733351 DOI: 10.1038/nrgastro.2012.119]
- 6 Hidalgo M. Pancreatic cancer. *N Engl J Med* 2010; **362**: 1605-1617 [PMID: 20427809 DOI: 10.1056/NEJMra0901557]
- 7 Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, Kosary C, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis D, Chen H, Feuer E, Cronin K. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD [Internet]. based Novemb. 2013 SEER data Submission. Available from: URL: http://seer.cancer.gov/csr/1975_2011/
- 8 Court CM, Ankeny JS, Hou S, Tseng HR, Tomlinson JS. Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis. *Expert Rev Mol Diagn* 2015; **15**: 1491-1504 [PMID: 26390158 DOI: 10.1586/14737159.2015.1091311]
- 9 Krempien R, Muenter MW, Harms W, Debus J. Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma. *HPB (Oxford)* 2006; **8**: 22-28 [PMID: 18333234 DOI: 10.1080/13651820500468034]
- 10 Herreros-Villanueva M, Gironella M, Castells A, Bujanda L. Molecular markers in pancreatic cancer diagnosis. *Clin Chim Acta* 2013; **418**: 22-29 [PMID: 23305796 DOI: 10.1016/j.cca.2012.12.025]
- 11 Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 1997; **15**: 2403-2413 [PMID: 9196156 DOI: 10.1200/JCO.1997.15.6.2403]
- 12 Sjoquist KM, Chin VT, Chantrill LA, O'Connor C, Hemmings C, Chang DK, Chou A, Pajic M, Johns AL, Nagrial AM, Biankin AV, Yip D. Personalising pancreas cancer treatment: When tissue is the issue. *World J Gastroenterol* 2014; **20**: 7849-7863 [PMID: 24976722 DOI: 10.3748/wjg.v20.i24.7849]
- 13 Yang ZY, Yuan JQ, Di MY, Zheng DY, Chen JZ, Ding H, Wu XY, Huang YF, Mao C, Tang JL. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. *PLoS One* 2013; **8**: e57528 [PMID: 23472089 DOI: 10.1371/journal.pone.0057528]
- 14 Di Marco M, Grassi E, Durante S, Vecchiarelli S, Palloni A, Macchini M, Casadei R, Ricci C, Panzacchi R, Santini D, Biasco G. State of the art biological therapies in pancreatic cancer. *World J Gastrointest Oncol* 2016; **8**: 55-66 [PMID: 26798437 DOI: 10.4251/wjgo.v8.i1.55]
- 15 Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2007; **25**: 1960-1966 [PMID: 17452677 DOI: 10.1200/JCO.2006.07.9525]
- 16 Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouf F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011; **364**: 1817-1825 [PMID: 21561347 DOI: 10.1056/NEJMoa1011923]
- 17 Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjuland SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Taberner J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013; **369**: 1691-1703 [PMID: 24131140 DOI: 10.1056/NEJMoa1304369]
- 18 Neoptolemos JP, Palmer D, Ghaneh P, Valle JW, Cunningham, David Wadsley J, Meyer T, Anthony A, Glimelius B, Falk S, Segersvard R, Izbicki JR, Middleton GW, Ross PJ, Wasan H, McDonald A, Crosby, Tom David Lewis Buchler MW. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcin. In: 2016 ASCO Annual Meeting. *J Clin Oncol* 2016; **34**
- 19 Fortner JG, Klimstra DS, Senie RT, Maclean BJ. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatotomy. *Ann Surg* 1996; **223**: 147-153 [PMID: 8597508 DOI: 10.1097/00000658-199602000-00006]
- 20 Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals

- kinetics of metastasis suggesting optimum treatment strategies. *Cell* 2012; **148**: 362-375 [PMID: 22265421 DOI: 10.1016/j.cell.2011.11.060.Computational]
- 21 **Hruban RH**, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. *Clin Cancer Res* 2000; **6**: 2969-2972 [PMID: 10955772]
 - 22 **Notta F**, Chan-Seng-Yue M, Lemire M, Li Y, Wilson GW, Connor AA, Denroche RE, Liang SB, Brown AM, Kim JC, Wang T, Simpson JT, Beck T, Borgida A, Buchner N, Chadwick D, Hafezi-Bakhtiari S, Dick JE, Heisler L, Hollingsworth MA, Ibrahimov E, Jang GH, Johns J, Jorgensen LG, Law C, Ludkovski O, Lungu I, Ng K, Pasternack D, Petersen GM, Shlush LI, Timms L, Tsao MS, Wilson JM, Yung CK, Zogopoulos G, Bartlett JM, Alexandrov LB, Real FX, Cleary SP, Roehrl MH, McPherson JD, Stein LD, Hudson TJ, Campbell PJ, Gallinger S. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. *Nature* 2016; **538**: 378-382 [PMID: 27732578 DOI: 10.1038/nature19823]
 - 23 **Moskaluk CA**, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. *Cancer Res* 1997; **57**: 2140-2143 [PMID: 9187111]
 - 24 **Yachida S**, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. *Nature* 2010; **467**: 1114-1117 [PMID: 20981102 DOI: 10.1038/nature09515]
 - 25 **Campbell PJ**, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C, Futreal PA. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. *Nature* 2010; **467**: 1109-1113 [PMID: 20981101 DOI: 10.1038/nature09460]
 - 26 **Weder N**, Zhang H, Jensen K, Yang BZ, Simen A, Jackowski A, Lipschitz D, Douglas-Palumberi H, Ge M, Perepletchikova F, O'Loughlin K, Hudziak JJ, Gelernter J, Kaufman J. Child abuse, depression, and methylation in genes involved with stress, neural plasticity, and brain circuitry. *J Am Acad Child Adolesc Psychiatry* 2014; **53**: 417-24.e5 [PMID: 24655651 DOI: 10.1016/j.jmolmed.2014.11.008.Mitochondria]
 - 27 **Jones S**, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffe EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008; **321**: 1801-1806 [PMID: 18772397 DOI: 10.1126/science.1164368]
 - 28 **Takai E**, Yachida S. Genomic alterations in pancreatic cancer and their relevance to therapy. *World J Gastrointest Oncol* 2015; **7**: 250-258 [PMID: 26483879 DOI: 10.4251/wjgo.v7.i10.250]
 - 29 **Philip PA**, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. *J Clin Oncol* 2009; **27**: 5660-5669 [PMID: 19858397 DOI: 10.1200/JCO.2009.21.9022]
 - 30 **Waddell N**, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrell LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA, Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM. Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature* 2015; **518**: 495-501 [PMID: 25719666 DOI: 10.1038/nature14169]
 - 31 **Bailey P**, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, Nourse C, Murtaugh LC, Harliwong I, Idrisoglu S, Manning S, Nourbakhsh E, Wani S, Fink L, Holmes O, Chin V, Anderson MJ, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Xu Q, Wilson PJ, Cloonan N, Kassahn KS, Taylor D, Quek K, Robertson A, Pantano L, Mincarelli L, Sanchez LN, Evers L, Wu J, Pinese M, Cowley MJ, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chantrell LA, Mawson A, Humphris J, Chou A, Pajic M, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Lovell JA, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Moran-Jones K, Jamieson NB, Graham JS, Duthie F, Oien K, Hair J, Grützmann R, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Rusev B, Capelli P, Salvia R, Tortora G, Mukhopadhyay D, Petersen GM, Munzy DM, Fisher WE, Karim SA, Eshleman JR, Hruban RH, Pilarsky C, Morton JP, Sansom OJ, Scarpa A, Musgrove EA, Bailey UM, Hofmann O, Sutherland RL, Wheeler DA, Gill AJ, Gibbs RA, Pearson JV, Waddell N, Biankin AV, Grimmond SM. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* 2016; **531**: 47-52 [PMID: 26909576 DOI: 10.1038/nature16965]
 - 32 **Collisson EA**, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. *Nat Med* 2011; **17**: 500-503 [PMID: 21460848 DOI: 10.1038/nm.2344.Subtypes]
 - 33 **Erkan M**, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, Friess H. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. *Nat Rev Gastroenterol Hepatol* 2012; **9**: 454-467 [PMID: 22710569 DOI: 10.1038/nrgastro.2012.115]
 - 34 **Erkan M**. Understanding the stroma of pancreatic cancer: co-evolution of the microenvironment with epithelial carcinogenesis. *J Pathol* 2013; **231**: 4-7 [PMID: 23716361 DOI: 10.1002/path.4213]
 - 35 **Koay EJ**, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Varadhachary GR, Ferrari M, Fleming JB. Transport properties of pancreatic cancer describe gemcitabine delivery and response. *J Clin Invest* 2014; **124**: 1525-1536 [PMID: 24614108 DOI: 10.1172/JCI173455]
 - 36 **North S**, Ansari D, Andersson R. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review. *World J Gastroenterol* 2014; **20**: 8482-8490 [PMID: 25024604 DOI: 10.3748/wjg.v20.i26.8482]
 - 37 **Young JD**, Yao SY, Sun L, Cass CE, Baldwin SA. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. *Xenobiotica* 2008; **38**: 995-1021 [PMID: 18668437 DOI: 10.1080/00498250801927427]
 - 38 **Spratlin J**, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. *Clin Cancer Res* 2004; **10**: 6956-6961 [PMID: 15501974 DOI: 10.1158/1078-0432.CCR-04-0224]
 - 39 **Greenhalf W**, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthony A, Halloran CM, Mayerle J, Oláh A, Jackson R, Rawcliffe CL, Scarpa A, Bassi C, Büchler MW. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. *J Natl Cancer Inst* 2014; **106**: djt347 [PMID:

- 24301456 DOI: 10.1093/jnci/djt347]
- 40 **Soo RA**, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. *Curr Drug Targets* 2012; **13**: 811-828 [PMID: 22458528 DOI: 10.1016/j.pestbp.2011.02.012. Investigations]
 - 41 **Moffitt RA**, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, Smyla JK, Anderson JM, Kim HJ, Bentrem DJ, Talamonti MS, Iacobuzio-Donahue CA, Hollingsworth MA, Yeh JJ. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. *Nat Genet* 2015; **47**: 1168-1178 [PMID: 26343385 DOI: 10.1038/ng.3398]
 - 42 **Bournet B**, Selves J, Grand D, Danjoux M, Hanoun N, Cordelier P, Buscail L. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer. *J Clin Gastroenterol* 2015; **49**: 50-56 [PMID: 24798941 DOI: 10.1097/MCG.000000000000053]
 - 43 **Tempero MA**, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinov BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA. Pancreatic adenocarcinoma. *J Natl Compr Canc Netw* 2010; **8**: 972-1017 [PMID: 20876541]
 - 44 **O'Brien DP**, Sandanayake NS, Jenkinson C, Gentry-Maharaj A, Apostolidou S, Fourkala EO, Camuzeaux S, Blyuss O, Gunu R, Dawnay A, Zaikin A, Smith RC, Jacobs IJ, Menon U, Costello E, Pereira SP, Timms JF. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. *Clin Cancer Res* 2015; **21**: 622-631 [PMID: 24938522 DOI: 10.1158/1078-0432.CCR-14-0365]
 - 45 **Winter JM**, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. *J Surg Oncol* 2013; **107**: 15-22 [PMID: 22729569 DOI: 10.1002/jso.23192]
 - 46 **Pleskow DK**, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. *Ann Intern Med* 1989; **110**: 704-709 [PMID: 2930108 DOI: 10.7326/0003-4819-110-9-704]
 - 47 **Berger AC**, Garcia M, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB, MacDonald J, Willett CG. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. *J Clin Oncol* 2008; **26**: 5918-5922 [PMID: 19029412 DOI: 10.1200/JCO.2008.18.6288]
 - 48 **Zhang Y**, Yang J, Li H, Wu Y, Zhang H, Chen W. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. *Int J Clin Exp Med* 2015; **8**: 11683-11691 [PMID: 26380005]
 - 49 **Barnett NP**, Apodaca TR, Magill M, Colby SM, Gwaltney C, Rohsenow DJ, Monti PM. Moderators and mediators of two brief interventions for alcohol in the emergency department. *Addiction* 2010; **105**: 452-465 [PMID: 20402989 DOI: 10.1038/nature09421. Oxidative]
 - 50 **Cwik G**, Wallner G, Skoczylas T, Ciecchanski A, Zinkiewicz K. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. *Arch Surg* 2006; **141**: 968-973; discussion 974 [PMID: 17043274 DOI: 10.1001/archsurg.141]
 - 51 **Gold DV**, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, Newsome G, Goldenberg DM. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. *Cancer* 2013; **119**: 522-528 [PMID: 22898932 DOI: 10.1002/ncr.27762]
 - 52 **Gold DV**, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. *Clin Cancer Res* 2007; **13**: 7380-7387 [PMID: 18094420 DOI: 10.1158/1078-0432.CCR-07-1488]
 - 53 **Brentnall TA**. Pancreatic cancer surveillance: learning as we go. *Am J Gastroenterol* 2011; **106**: 955-956 [PMID: 21540900 DOI: 10.1038/ajg.2011.68]
 - 54 **Templeton AW**, Brentnall TA. Screening and surgical outcomes of familial pancreatic cancer. *Surg Clin North Am* 2013; **93**: 629-645 [PMID: 23632149 DOI: 10.1016/j.suc.2013.02.002]
 - 55 **Capurso G**, Signoretti M, Valente R, Arnelo U, Lohr M, Poley JW, Delle Fave G, Del Chiaro M. Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals. *World J Gastrointest Endosc* 2015; **7**: 833-842 [PMID: 26240684 DOI: 10.4253/wjge.v7.i9.833]
 - 56 **Laeseke PF**, Chen R, Jeffrey RB, Brentnall TA, Willmann JK. Combining in Vitro Diagnostics with in Vivo Imaging for Earlier Detection of Pancreatic Ductal Adenocarcinoma: Challenges and Solutions. *Radiology* 2015; **277**: 644-661 [PMID: 26599925 DOI: 10.1148/radiol.2015141020]
 - 57 **Edge S**, Byrd D, Compton C, Fritz A, Greene F, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer, 2010
 - 58 **Saeed-vafa D**, Magliocco AM. Practical Applications of Digital Pathology. *Cancer Control* 2015; **22**: 137-141
 - 59 **Gurcan MN**, Boucheron LE, Can A, Madabhushi A, Rajpoot NM, Yener B. Histopathological image analysis: a review. *IEEE Rev Biomed Eng* 2009; **2**: 147-171 [PMID: 20671804 DOI: 10.1109/RBME.2009.2034865.Histopathological]
 - 60 **Langer L**, Binenbaum Y, Gugel L, Amit M, Gil Z, Dekel S. Computer-aided diagnostics in digital pathology: automated evaluation of early-phase pancreatic cancer in mice. *Int J Comput Assist Radiol Surg* 2015; **10**: 1043-1054 [PMID: 25354901 DOI: 10.1007/s11548-014-1122-9]
 - 61 **Song JW**, Lee JH. New morphological features for grading pancreatic ductal adenocarcinomas. *Biomed Res Int* 2013; **2013**: 175271 [PMID: 23984321 DOI: 10.1155/2013/175271]
 - 62 **Song JW**, Lee JH, Choi JH, Chun SJ. Automatic differential diagnosis of pancreatic serous and mucinous cystadenomas based on morphological features. *Comput Biol Med* 2013; **43**: 1-15 [PMID: 23200461 DOI: 10.1016/j.combiomed.2012]
 - 63 **Pantanowitz L**, Sinarid JH, Henricks WH, Fatheree LA, Carter AB, Contis L, Beckwith BA, Evans AJ, Lal A, Parwani AV. Validating whole slide imaging for diagnostic purposes in pathology: guideline from the College of American Pathologists Pathology and Laboratory Quality Center. *Arch Pathol Lab Med* 2013; **137**: 1710-1722 [PMID: 23634907 DOI: 10.5858/arpa.2013-0093-CP]
 - 64 **Anderson N**, Badano A. Technical performance assessment of digital pathology whole slide imaging devices [Internet]. *Guid Ind Food Drug Adm Staff* 2016. Available from: URL: <http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM435355.pdf>
 - 65 **Morroney R**. FDA intends to reclassify digital pathology systems. *Inspirata* [Internet] 2016. Available from: URL: <http://www.inspirata.com/fda-intends-to-reclassify-digital-pathology-systems/>
 - 66 **Harsha HC**, Kandasamy K, Ranganathan P, Rani S, Ramabadrans S, Gollapudi S, Balakrishnan L, Dwivedi SB, Telikicherla D, Selvan LD, Goel R, Mathivanan S, Marimuthu A, Kashyap M, Vizza RF, Mayer RJ, Decaprio JA, Srivastava S, Hanash SM, Hruban RH, Pandey A. A compendium of potential biomarkers of pancreatic cancer. *PLoS Med* 2009; **6**: e1000046 [PMID: 19360088 DOI: 10.1371/journal.pmed.1000046]
 - 67 **Rhim AD**, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ. EMT and dissemination precede pancreatic tumor formation. *Cell* 2012; **148**: 349-361 [PMID: 22265420 DOI: 10.1016/j.cell.2011.11.025.EMT]
 - 68 **Mani SA**, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Briskin C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 2008; **133**: 704-715 [PMID: 18485877 DOI: 10.1016/j.cell.2008.03.027.The]
 - 69 **Tjensvoll K**, Nordgård O, Smaaland R. Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. *Int J Cancer* 2014; **134**: 1-8 [PMID: 23447365 DOI: 10.1002/ijc.28134]
 - 70 **De Giorgi U**, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli

- M. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. *J Clin Oncol* 2009; **27**: 3303-3311 [PMID: 19451443 DOI: 10.1200/JCO.2008.19.4423]
- 71 **Cristofanilli M**, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *N Engl J Med* 2004; **351**: 781-791 [PMID: 15317891 DOI: 10.1056/NEJMoa040766]
- 72 **de Bono JS**, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. *Clin Cancer Res* 2008; **14**: 6302-6309 [PMID: 18829513 DOI: 10.1158/1078-0432.CCR-08-0872]
- 73 **Cohen SJ**, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. *J Clin Oncol* 2008; **26**: 3213-3221 [PMID: 18591556 DOI: 10.1200/JCO.2007.15.8923]
- 74 **Krebs MG**, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G, Ranson M, Dive C, Blackhall FH. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. *J Clin Oncol* 2011; **29**: 1556-1563 [PMID: 21422424 DOI: 10.1200/JCO.2011.20.1556]
- 75 **Miyazono F**, Takao S, Natsugoe S, Uchikura K, Kijima F, Aridome K, Shinchi H, Aikou T. Molecular detection of circulating cancer cells during surgery in patients with biliary-pancreatic cancer. *Am J Surg* 1999; **177**: 475-479 [PMID: 10414697 DOI: 10.1016/S0002-9610(99)00086-0]
- 76 **de Albuquerque A**, Kubisch I, Breier G, Stamminger G, Fersis N, Eichler A, Kaul S, Stölzel U. Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. *Oncology* 2012; **82**: 3-10 [PMID: 22270149 DOI: 10.1159/000335479]
- 77 **Bobek V**, Gurlich R, Eliasova P, Kolostova K. Circulating tumor cells in pancreatic cancer patients: enrichment and cultivation. *World J Gastroenterol* 2014; **20**: 17163-17170 [PMID: 25493031 DOI: 10.3748/wjg.v20.i45.17163]
- 78 **Riva F**, Dronov OI, Khomenko DI, Huguet F, Louvet C, Mariani P, Stern MH, Lantz O, Proudhon C, Pierga JY, Bidard FC. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. *Mol Oncol* 2016; **10**: 481-493 [PMID: 26856794 DOI: 10.1016/j.molonc.2016.01.006]
- 79 **Nagrath S**, Jack RM, Sahai V, Simeone DM. Opportunities and Challenges for Pancreatic Circulating Tumor Cells. *Gastroenterology* 2016; **151**: 412-426 [PMID: 27339829 DOI: 10.1053/j.gastro.2016.05.052]
- 80 **Allard WJ**, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. *Clin Cancer Res* 2004; **10**: 6897-6904 [PMID: 15501967 DOI: 10.1158/1078-0432.CCR-04-0378]
- 81 **Bidard FC**, Huguet F, Louvet C, Mineur L, Bouché O, Chibaudel B, Artru P, Desseigne F, Bachet JB, Mathiot C, Pierga JY, Hammel P. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. *Ann Oncol* 2013; **24**: 2057-2061 [PMID: 23676420 DOI: 10.1093/annonc/mdl176]
- 82 **Khoja L**, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, Board R, Clack G, Hughes A, Blackhall F, Valle JW, Dive C. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. *Br J Cancer* 2012; **106**: 508-516 [PMID: 22187035 DOI: 10.1038/bjc.2011.545]
- 83 **Bissolati M**, Sandri MT, Burtulo G, Zorzino L, Balzano G, Braga M. Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer. *Tumour Biol* 2015; **36**: 991-996 [PMID: 25318603 DOI: 10.1007/s13277-014-2716-0]
- 84 **Kurihara T**, Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Tsuji S, Ishii K, Ikeuchi N, Tsuchida A, Kasuya K, Kawai T, Sakai Y, Moriyasu F. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. *J Hepatobiliary Pancreat Surg* 2008; **15**: 189-195 [PMID: 18392713 DOI: 10.1007/s00534-007-1250-5]
- 85 **Earl J**, Garcia-Nieto S, Martinez-Avila JC, Montans J, Sanjuanbenito A, Rodríguez-Garrote M, Lisa E, Mendía E, Lobo E, Malats N, Carrato A, Guillen-Ponce C. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. *BMC Cancer* 2015; **15**: 797 [PMID: 26498594 DOI: 10.1186/s12885-015-1779-7]
- 86 **Parkinson DR**, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar P, Lee JSh, Liu MC, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose EA, Roadcap LT, Schade AE, Scher HI, Sigman CC, Kelloff GJ. Considerations in the development of circulating tumor cell technology for clinical use. *J Transl Med* 2012; **10**: 138 [PMID: 22747748 DOI: 10.1186/1479-5876-10-138]
- 87 **Vona G**, Sabile A, Louha M, Sitruk V, Romana S, Schütze K, Capron F, Franco D, Pazzagli M, Vekemans M, Lacour B, Bréchet C, Paterlini-Bréchet P. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. *Am J Pathol* 2000; **156**: 57-63 [PMID: 10623654 DOI: 10.1016/S0002-9440(10)64706-2]
- 88 **Paterlini-Bréchet P**. Circulating Tumor Cells: Who is the Killer? *Cancer Microenviron* 2014; **7**: 161-176 [PMID: 25527469 DOI: 10.1007/s12307-014-0164-4]
- 89 **Thiery JP**. Epithelial-mesenchymal transitions in tumour progression. *Nat Rev Cancer* 2002; **2**: 442-454 [PMID: 12189386 DOI: 10.1038/nrc822]
- 90 **Went PT**, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S. Frequent EpCam protein expression in human carcinomas. *Hum Pathol* 2004; **35**: 122-128 [PMID: 14745734 DOI: 10.1016/S0046-8177(03)00502-1]
- 91 **Ren C**, Han C, Zhang J, He P, Wang D, Wang B, Zhao P, Zhao X. Detection of apoptotic circulating tumor cells in advanced pancreatic cancer following 5-fluorouracil chemotherapy. *Cancer Biol Ther* 2011; **12**: 700-706 [PMID: 21811100 DOI: 10.4161/cbt.12.8.15960]
- 92 **Court CM**, Ankeny JS, Sho S, Hou S, Li Q, Hsieh C, Song M, Liao X, Rochefort MM, Wainberg ZA, Graeber TG, Tseng HR, Tomlinson JS. Reality of Single Circulating Tumor Cell Sequencing for Molecular Diagnostics in Pancreatic Cancer. *J Mol Diagn* 2016; **18**: 688-696 [PMID: 27375074 DOI: 10.1016/j.jmoldx.2016.03.006]
- 93 **Chausovsky G**, Luchansky M, Figer A, Shapira J, Gottfried M, Novis B, Bogelman G, Zemer R, Zimlichman S, Klein A. Expression of cytokeratin 20 in the blood of patients with disseminated carcinoma of the pancreas, colon, stomach, and lung. *Cancer* 1999; **86**: 2398-2405 [PMID: 10590383 DOI: 10.1002/(SICI)1097-0142(19991201)86:11<2398::AID-CNCR30>3.3.CO;2-X]
- 94 **Soeth E**, Grigoleit U, Moellmann B, Röder C, Schniewind B, Kremer B, Kalthoff H, Vogel I. Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. *J Cancer Res Clin Oncol* 2005; **131**: 669-676 [PMID: 16136352 DOI: 10.1007/s00432-005-0008-1]
- 95 **Chu P**, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. *Mod Pathol* 2000; **13**: 962-972 [PMID: 11007036 DOI: 10.1038/modpathol.3880175]
- 96 **Zhou J**, Hu L, Yu Z, Zheng J, Yang D, Bouvet M, Hoffman RM. Marker expression in circulating cancer cells of pancreatic cancer patients. *J Surg Res* 2011; **171**: 631-636 [PMID: 20869080 DOI: 10.1016/j.jss.2011.05.001]
- 97 **Ankeny JS**, Hou S, Lin M, OuYang H, Song M, Rochefort MM, Girgis MD, Isacoff WH, Wainberg ZA, Tseng H-R, Tomlinson JS. Pancreatic circulating tumor cells as a diagnostic adjunct in pancreatic cancer. *J Clin Oncol* 2014; Abstract 175
- 98 **Yu M**, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, Milos PM, Ryan DP, Sequist LV, Bardeesy N, Ramaswamy S, Toner M, Maheswaran S, Haber DA. RNA sequencing of pancreatic circulating tumour cells implicates

- WNT signalling in metastasis. *Nature* 2012; **487**: 510-513 [PMID: 22763454 DOI: 10.1038/nature11217]
- 99 **Ting DT**, Wittner BS, Ligorio M, Vincent Jordan N, Shah AM, Miyamoto DT, Aceto N, Bersani F, Brannigan BW, Xega K, Ciciliano JC, Zhu H, MacKenzie OC, Trautwein J, Arora KS, Shahid M, Ellis HL, Qu N, Bardeesy N, Rivera MN, Deshpande V, Ferrone CR, Kapur R, Ramaswamy S, Shioda T, Toner M, Maheswaran S, Haber DA. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. *Cell Rep* 2014; **8**: 1905-1918 [PMID: 25242334 DOI: 10.1016/j.celrep.2014.08.029. Single-Cell]
- 100 **Lohr JG**, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang CZ, Shalek AK, Satija R, Trombetta JJ, Lu D, Tallapragada N, Tahirova N, Kim S, Blumenstiel B, Sougnez C, Lowe A, Wong B, Auclair D, Van Allen EM, Nakabayashi M, Lis RT, Lee GS, Li T, Chabot MS, Ly A, Taplin ME, Clancy TE, Loda M, Regev A, Meyerson M, Hahn WC, Kantoff PW, Golub TR, Getz G, Boehm JS, Love JC. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. *Nat Biotechnol* 2014; **32**: 479-484 [PMID: 24752078 DOI: 10.1038/nbt.2892]
- 101 **Witkiewicz AK**, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, Mollaei M, Wagner KU, Koduru P, Yopp A, Choti MA, Yeo CJ, McCue P, White MA, Knudsen ES. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. *Nat Commun* 2015; **6**: 6744 [PMID: 25855536 DOI: 10.1038/ncomms7744]
- 102 **Jiao Y**, Yonescu R, Offerhaus GJ, Klimstra DS, Maitra A, Eshleman JR, Herman JG, Poh W, Pelosof L, Wolfgang CL, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N, Wood LD. Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. *J Pathol* 2014; **232**: 428-435 [PMID: 24293293 DOI: 10.1002/path.43]
- 103 **Zill OA**, Greene C, Sebisano D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasz A, Collisson EA. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. *Cancer Discov* 2015; **5**: 1040-1048 [PMID: 26109333 DOI: 10.1158/2159-8290.CD-15-0274.Cell-free]
- 104 **Berger AW**, Schwerdel D, Costa IG, Hackert T, Strobel O, Lam S, Barth TF, Schröppel B, Meining A, Büchler MW, Zenke M, Hermann PC, Seufferlein T, Kleger A. Detection of Hot-Spot Mutations in Circulating Cell-Free DNA From Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas. *Gastroenterology* 2016; **151**: 267-270 [PMID: 27343369 DOI: 10.1053/j.gastro.2016.04.034]
- 105 **Lewis AR**, Valle JW, McNamara MG. Pancreatic cancer: Are "liquid biopsies" ready for prime-time? *World J Gastroenterol* 2016; **22**: 7175-7185 [PMID: 27621566 DOI: 10.3748/wjg.v22.i32.7175]
- 106 **Harewood GC**, Wiersema MJ. A cost analysis of endoscopic ultrasound in the evaluation of pancreatic head adenocarcinoma. *Am J Gastroenterol* 2001; **96**: 2651-2656 [PMID: 11569690 DOI: 10.1111/j.1572-0241.2001.04116.x]
- 107 **CMS.gov**. 2015 Medicare Clinical Laboratory Fee Schedule. [Internet]. Cent. Medicare Medicaid 2015. Available from: URL: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html>
- 108 **Verma M**, Lam TK, Hebert E, Divi RL. Extracellular vesicles: potential applications in cancer diagnosis, prognosis, and epidemiology. *BMC Clin Pathol* 2015; **15**: 6 [PMID: 25883534 DOI: 10.1186/s12907-015-0005-5]
- 109 **Nabhan JF**, Hu R, Oh RS, Cohen SN, Lu Q. Formation and release of arrestin domain-containing protein 1-mediated microvesicles (ARMMs) at plasma membrane by recruitment of TSG101 protein. *Proc Natl Acad Sci USA* 2012; **109**: 4146-4151 [PMID: 22315426]
- 110 **Taylor DD**, Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. *Semin Immunopathol* 2011; **33**: 441-454 [PMID: 21688197 DOI: 10.1007/s00281-010-0234-8]
- 111 **Robinson SM**, Fan L, White SA, Charnley RM, Mann J. The role of exosomes in the pathogenesis of pancreatic ductal adenocarcinoma. *Int J Biochem Cell Biol* 2016; **75**: 131-139 [PMID: 27017975 DOI: 10.1016/j.biocel.2016.03.009]
- 112 **Munson P**, Shukla A. Exosomes: Potential in Cancer Diagnosis and Therapy. *Medicines* (Basel) 2015; **2**: 310-327 [PMID: 27088079 DOI: 10.3390/medicines2040310]
- 113 **An T**, Qin S, Xu Y, Tang Y, Huang Y, Situ B, Inal JM, Zheng L. Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. *J Extracell Vesicles* 2015; **4**: 27522 [PMID: 26095380 DOI: 10.3402/jev.v4.27522]
- 114 **Hidalgo M**, Plaza C, Musteanu M, Illei P, Brachmann CB. SPARC Expression Did Not Predict Efficacy of nab -Paclitaxel Plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. *Clin Cancer Res* 2015; In press
- 115 **Sheridan C**. Exosome cancer diagnostic reaches market. *Nat Biotechnol* 2016; **34**: 359-360 [PMID: 27054974 DOI: 10.1038/nbt0416-359]
- 116 **Baietti MF**, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, Ivarsson Y, Depoortere F, Coomans C, Vermeiren E, Zimmermann P, David G. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. *Nat Cell Biol* 2012; **14**: 677-685 [PMID: 22660413 DOI: 10.1038/ncb2502]
- 117 **Melo SA**, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnicka-Worms D, Kalluri R. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. *Nature* 2015; **523**: 177-182 [PMID: 26106858 DOI: 10.1038/nature14581]
- 118 **Siveke JT**, Crawford HC. KRAS above and beyond - EGFR in pancreatic cancer. *Oncotarget* 2012; **3**: 1262-1263 [PMID: 23174662 DOI: 10.18632/oncotarget.750]
- 119 **Adamczyk KA**, Klein-Scory S, Tehrani MM, Warnken U, Schmiegel W, Schnölzer M, Schwarte-Waldhoff I. Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells. *Life Sci* 2011; **89**: 304-312 [PMID: 21763319 DOI: 10.1016/j.lfs.2011.06.020]
- 120 **Ciravolo V**, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, Morelli D, Villa A, Della Mina P, Menard S, Filipazzi P, Rivoltini L, Tagliabue E, Pupa SM. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. *J Cell Physiol* 2012; **227**: 658-667 [PMID: 21465472 DOI: 10.1002/jcp.22773]
- 121 **Smit VT**, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. *Nucleic Acids Res* 1988; **16**: 7773-7782 [PMID: 3047672 DOI: 10.1093/nar/16.16.7773]
- 122 **Almoguera C**, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. *Cell* 1988; **53**: 549-554 [PMID: 2453289 DOI: 10.1016/0092-8674(88)90571-5]
- 123 **Kahlert C**, Melo SA, Protopopov A, Tang J, Seth S, Koch M, Zhang J, Weitz J, Chin L, Futreal A, Kalluri R. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. *J Biol Chem* 2014; **289**: 3869-3875 [PMID: 24398677 DOI: 10.1074/jbc.C113.532267]
- 124 **San Lucas FA**, Allenson K, Bernard V, Castillo J, Kim DU, Ellis K, Ehli EA, Davies GE, Petersen JL, Li D, Wolff R, Katz M, Varadhachary G, Wistuba I, Maitra A, Alvarez H. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. *Ann Oncol* 2016; **27**: 635-641 [PMID: 26681674 DOI: 10.1093/annonc/mdv604]
- 125 **Charrier A**, Chen R, Chen L, Kemper S, Hattori T, Takigawa M, Brigstock DR. Connective tissue growth factor (CCN2) and microRNA-21 are components of a positive feedback loop in pancreatic stellate cells (PSC) during chronic pancreatitis and are exported in PSC-derived exosomes. *J Cell Commun Signal* 2014; **8**: 147-156 [PMID: 24464300 DOI: 10.1007/s12079-014-0220-3]
- 126 **Ding G**, Zhou L, Qian Y, Fu M, Chen J, Chen J, Xiang J, Wu Z, Jiang G, Cao L. Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. *Oncotarget* 2015; **6**: 29877-29888 [PMID: 26337469 DOI: 10.18632/oncotarget.4924]

- 127 **Patel GK**, Patton MC, Singh S, Khushman M, Singh AP. Pancreatic Cancer Exosomes: Shedding Off for a Meaningful Journey. *Pancreat Disord Ther* 2016; **6**: e148 [PMID: 27030812 DOI: 10.4172/2165-7092.1000e148.Pancreatic]
- 128 **Que R**, Ding G, Chen J, Cao L. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. *World J Surg Oncol* 2013; **11**: 219 [PMID: 24007214 DOI: 10.1186/1477-7819-11-219]
- 129 **Christianson HC**, Svensson KJ, van Kuppevelt TH, Li JP, Belting M. Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. *Proc Natl Acad Sci USA* 2013; **110**: 17380-17385 [PMID: 24101524]
- 130 **Hoshino A**, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplod N, Uryu K, Pharmed L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D. Tumour exosome integrins determine organotropic metastasis. *Nature* 2015; **527**: 329-335 [PMID: 26524530 DOI: 10.1038/nature15756]
- 131 **Mulcahy LA**, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. *J Extracell Vesicles* 2014; **3** [PMID: 25143819 DOI: 10.3402/jev.v3.24641]
- 132 **Costa-Silva B**, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen TM, Garcia-Santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen TL, Labori KJ, Lothe IM, Kure EH, Hernandez J, Doussot A, Ebbesen SH, Grandgenett PM, Hollingsworth MA, Jain M, Mallya K, Batra SK, Jarnagin WR, Schwartz RE, Matei I, Peinado H, Stanger BZ, Bromberg J, Lyden D. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. *Nat Cell Biol* 2015; **17**: 816-826 [PMID: 25985394 DOI: 10.1038/ncb3169]
- 133 **Wang F**, Herrington M, Larsson J, Permert J. The relationship between diabetes and pancreatic cancer. *Mol Cancer* 2003; **2**: 4 [PMID: 12556242 DOI: 10.1186/1476-4598-2-1]
- 134 **Javeed N**, Sagar G, Dutta SK, Smyrk TC, Lau JS, Bhattacharya S, Truty M, Petersen GM, Kaufman RJ, Chari ST, Mukhopadhyay D. Pancreatic Cancer-Derived Exosomes Cause Paraneoplastic β -cell Dysfunction. *Clin Cancer Res* 2015; **21**: 1722-1733 [PMID: 25355928 DOI: 10.1158/1078-0432.CCR-14-2022.Pancreatic]

P- Reviewer: Kleeff J, Matsuda Y, McNamara MG, Ocker M

S- Editor: Ji FF **L- Editor:** A **E- Editor:** Lu YJ

